Szpital Specjalistyczny Nr I W Bytomiu SPZOZ

Bytom 9 trials 4 recruiting

9 Registered trials

4 Currently recruiting

Organisation

Szpital Specjalistyczny Nr I W Bytomiu SPZOZ

Location

Bytom, Poland

Identifier

ORG-100045193

Address

Ul. Stefana Zeromskiego 7, 41-902, Poland

Departments

#3204 - Oddział Reumatologii i Rehabilitacji
#3204:Oddział Reumatologii i Rehabilitacji
2302: Oddział Rumatologii i Rehabilitacji
NA
Oddzial Reumatologii i Rehabilitacji
Oddział Reumatologii i Rehabilitacji

Clinical trials at this site (9)

Search interface

A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases Recruiting

2024-517681-41-00 Systemic Sclerosis 1 2025-08-29
Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting

2023-505929-14-00 Systemic Lupus Erythematosus 5 2024-05-21
A study of MK-7240/PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease Recruiting

2023-509743-27-00 Systemic sclerosis associated with interstitial lung di 4 2022-04-29
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting

2023-504201-36-00 Defined by parent protocol. The study will enroll all a 10 2018-12-21
A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu… Ended

2023-508077-85-00 Polymyalgia Rheumatica 5 2024-11-19
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Systemic Lupus Erythematosus 5 2023-02-03
Study of CC-97540 (BMS-986353), CD19-CAR T Cells, in Participants with Active SLE Despite Immunosuppressants (Breakfree-SLE) Halted

2024-519278-37-00 Lupus Nephritis 4 2025-10-22
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended

2022-501895-25-00 Polymyalgia Rheumatica 5 2023-09-13
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended

2023-504239-41-00 Hepatitis B, Chronic 5 2023-01-09